NEW YORK, July 4 - Patents are undoubtedly a hot topic in biotech and pharmaceuticals. A company’s intellectual property strategy is often more important than its core technology in the race to win market dominance. This, of course, is not only they case with the brass ring at the end of the pipeline – the drugs themselves – but almost every component of the drug development process, from gene sequence to chemical compounds and to the enabling technologies that make discovery possible. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.